JP Morgan analyst Steven Alexopoulos maintains Comerica (NYSE:CMA) with a Overweight and lowers the price target from $108 to $97.
HC Wainwright & Co. Maintains Buy on Cara Therapeutics, Lowers Price Target to $30
HC Wainwright & Co. analyst Oren Livnat maintains Cara Therapeutics (NASDAQ:CARA) with a Buy and lowers the price target from $35 to $30.